LivaNova PLC (NASDAQ:LIVN) Files An 8-K Entry into a Material Definitive Agreement

LivaNova PLC (NASDAQ:LIVN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.

Story continues below

Finance Contract

On June 29, 2017, LivaNova Plc (the “Company”) along with its subsidiaries, Sorin CRM S.A.S. and Sorin Group Italia S.r.l. (together, the “Borrowers”) entered into a finance contract (the “Finance Contract”) with the European Investment Bank (the “EIB”) by which the EIB established a credit facility in the amount of €100 million in favor of the Borrowers, which facility can be drawn in up to two tranches, each in a minimum amount of €50 million (or US dollar equivalent). Drawdowns must occur by December 30, 2018, and the last repayment date of any tranche will be no earlier than four years and no later than eight years after the disbursement of the relevant tranche. Loans under the facility contemplated by the Finance Contract are subject to certain covenants and other terms and conditions.

The foregoing description of the Finance Contract does not purport to be complete and is qualified in its entirety by reference to the full texts thereof filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.

Description

10.1

Finance Contract among the European Investment Bank, LivaNova Plc, Sorin CRM S.A.S., and Soring Group Italia S.r.l. dated June 29, 2017.


LivaNova PLC Exhibit
EX-10.1 2 eibfinancecontract.htm FINANCE CONTRACT Exhibit EXHIBIT 10.1FI N° 86.677 (IT)Serapis N° 2016-0607LIVANOVA R&DFinance Contractbetween theEuropean Investment BankandLivaNova PLCandSorin CRM S.A.S.andSorin Group Italia S.r.l.Luxembourg,…
To view the full exhibit click here

About LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing. The CRM business unit develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. CRM offers products, including leads and delivery systems, and information systems. The Neuromodulation business unit designs, develops and markets neuromodulation-based medical devices for the treatment of epilepsy and depression. Through the Neuromodulation business unit, the Company markets its implantable VNS Therapy systems that deliver vagus nerve stimulation therapy for the treatment of epilepsy and depression.

An ad to help with our costs